CDH1 and prostate carcinoma: We identified nine significant targets relevant to the treatment of prostate cancer, including KLK3, CCND1, EPHB2, and SRD5A1, as well as five core targets: PIK3CA, TP53, CTNNB1, CDH1, and AR.